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Letter to the Editor
healthcare and Ranbaxy have been bought by Abbott 
and Daiichi Sankyo, respectively.[3] Cipla, an indigenous 
company, lone with a market share of about 5.4% tops the 
list of top 10 companies in India. The increasing presence 
of foreign companies among the top pharmaceutical 
companies in India is may be due to a few buyouts which 
happened in the recent past. Daiichi Sankyo, a leading 
Japanese pharmaceutical company, which is actually a joint 
holding company of Sankyo Co. Ltd. and Daiichi Co. Ltd. 
had acquired a majority stake in Ranbaxy Laboratories, 
the then number one pharmaceutical company in India. 
Recently, in 2010, Hospira, a US‑based global specialty 
pharmaceutical and medication delivery company acquired 
Orchid Chemicals injectable business for US$ 400 
million; Abbott, a US‑based company, acquired Piramal 
Healthcare’s domestic formulations business for US$ 
3.7 billion; and Reckitt Benckiser, a UK‑based company 
bought Paras Pharma for US$ 720 million. It is said that 
if the takeovers continue, soon foreign pharmaceutical 
companies control nearly 50% of Indian drug retail 
market.[2] The impact of such takeovers would be anything 
from surge in drug prices to market supremacy by foreign 
companies. Issue of concern is that the companies which 
were taken over by foreign companies are major producers 
of cheaper generic versions of essential medicines and 
vaccines with extensive market reach in India and other 
developing countries.[4] 
Currently, there is 100% foreign direct investment (FDI) 
through automatic route. Stake holders of pharmaceutical 
industry had suggested imposing a cap of 49% and shifting 
from automatic route to Government route. Jyotiraditya 
Scindia, Minister of State for Commerce and Industry, 
said that the government has initiated interdepartmental 
consultations to address this important issue.[5]
It is not just the duty of Ministry of State for Commerce 
and Industry but all the concerned ministries of 
Government of India which govern pharmaceutical 
industry to look into the buyouts of Indian pharmaceutical 
companies by foreign pharmaceutical companies and its 
possible impact. The time has arisen to come out with 
suitable policy which would stop possible adversities of 
such takeovers.
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Sir,
Indian pharmaceutical industry has climbed the ladder to 
reach third position in terms of volume and fourteenth 
position in value terms. It is estimated to be worth US$ 4.5 
billion at annual growth rate of 8‑9%. India exports generic 
medicines worth US$ 11 billion and is considered to be 
the world’s largest. It is estimated to grow at a compound 
annual growth rate (CAGR) of 17% between 2010‑11 and 
2012‑13. As stated by Department of Pharmaceuticals, the 
total turnover of pharmaceutical industry in India was US$ 
21.04 billion during September 2008 and September 2009, 
of which the domestic market was worth US$ 12.26 billion. 
The Indian pharmaceutical market is expected to reach US$ 
55 billion by 2020 at the present growth rate and is said to 
have a potential to reach US$ 70 billion if the growth rate 
is aggressive. Domestic pharmaceutical market in India was 
about US$ 12 billion in 2010. Estimates say that it would 
reach to US$ 49 billion at a CAGR of 15 per cent. Indian 
diagnostic service and clinical trial services were also said 
to be growing at a faster pace.[1]
India’s pharmaceutical industry has emerged from 
almost nonexisting to a world leader in production of 
high‑quality generic drugs. It meets around 70% of 
the country’s demand for bulk drugs and formulations. 
Contract manufacturing, Foreign Direct Investment 
policy, drug regulatory reforms, reverse engineering of 
patented products, Trade‑Related Intellectual Property 
agreement are a few factors behind the success story. 
However, foreign drug manufacturers are poised to 
recuperate their dominance soon. There were barely 
two foreign companies among top 10 pharmaceutical 
companies in India in the year 2007 and presently three 
out of top five are foreign companies.[2] Also only two out 
of top 10 selling brands are from Indian pharmaceutical 
companies. Mocef by Aristo Pharma at seventh position 
and Taxim by Alkem at tenth position as Piramal Letter to the Editor
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